A biomedical engineering alliance strengthens the partnership between the University of Sydney and Shanghai Jiaotong University. [ + ]

Researchers have discovered how our immune cells and gluten interact at the amino acid level to trigger coeliac disease. [ + ]

Californian researchers have recorded a new world record for the fastest running land animal - one which is no bigger than a sesame seed in size. [ + ]

MiReven has picked up its first US patent for the microRNA precursor based anticancer technology developed by the Harry Perkins Institute of Medical Research. [ + ]

Australian, US and Dutch researchers have determined the molecular details of the interaction between the immune system and gluten that triggers coeliac disease. [ + ]

Mesoblast (ASX:MSB) will soon meet with the US FDA to discuss ways to accelerate the approval process for Prochymal, a stem cell-based treatment bought from Osiris Therapeutics, in GVHD. [ + ]

Australian researchers are using the tracer principle to confirm the presence of plastics and chemicals in the food chain. The research began when Professor Richard Banati and Dr Jennifer Laver found elements in the feathers of seabirds which were similar to those found in plastics in its gut. [ + ]

A study has shown that fast-growing cancer cells are sensitive towards imbalances in the metabolism of nucleotides, the building blocks of DNA - a vulnerability that can be exploited for a novel anti-tumour therapeutic approach. [ + ]

A chemical has been identified that provides broad spectrum disease protection in plants. [ + ]

Nominations are open for two Victoria Prizes for Science & Innovation and the 2014 Victoria Fellowships. [ + ]

Lonza Bioscience Singapore has received cGMP certification from the Singapore Health Sciences Authority (HSA) for its cell-therapy manufacturing facility, while Lonza Group has announced changes in the composition of its executive committee (EC). [ + ]

Specialised Therapeutics Australia has become the exclusive distributor in ANZ for Iluvien, a DMO treatment being commercialised by Alimera Sciences under licence from pSivida (ASX:PVA). [ + ]

Environmental scientist Daniel Meloncelli has been awarded a University of the Sunshine Coast (USC) Chancellor's Medal. It was one of only three Chancellor's Medals presented at USC's recent graduation ceremonies, awarded to outstanding graduates who have contributed to the university or wider community and achieved a high academic level during their studies. [ + ]

The 2014 BioBusiness Asia Conference, this year combined with BioTaiwan Exhibition 2014 to enlarge the partnering candidate pool, is calling for proposals from companies interested in presenting. [ + ]

Prima BioMed (ASX:PRR) has signed up the first patient for CAN-004, its phase II trial of therapy candidate CVac in epithelial ovarian cancer. [ + ]